PharmaEngine, Inc. (TWO:4162) announces the receiving of notice from partner IPSEN regarding ONIVYDE's 2024 sales in Europe and Asia reaching the second sales milestone, therefore, PharmaEngine will receive US$50 million of milestone payment.

 

 

* * *

 

About PharmaEngine, Inc

PharmaEngine, Inc., headquartered in Taipei, began operations in February 2003. PharmaEngine focuses on new drug development by adopting “Virtual Pharmaceutical Company Business Model” to reduce potential risks during the process of new drug development. PharmaEngine has one commercial product, ONIVYDE®, which has received marketing approvals in more than 50 countries worldwide for the treatment of metastatic pancreatic cancer patients who have progressed on gemcitabine. In addition, PEP07, which is a checkpoint kinase 1 (CHK1) inhibitor that targets the DNA Damage Response (DDR) pathway, is currently undergoing Phase 1 clinical trials. PharmaEngine also conducts, collaborates or licenses-in early-stage new drug discovery and development projects. With extensive experience in drug development and project management, we continue to promote and expand our pipeline, and accelerate drug development and the subsequent commercialization of new medicines.

Media Contact: ChiHsing Chang, Spokesperson/Vice President (info@pharmaengine.com)